Clinical trial · Interventional
Evaluation of HPV OncoTect ™ for the Etiological Diagnosis of HPV-induced Oropharyngeal Cancers
NCT03604588CI-TRIAL-00034009HPV OncoTect™unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the sensitivity of HPV OncotectTM to diagnose oropharyngeal cancers induced by oncogenic HPV
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oropharyngeal Cancer | Malignant Oropharyngeal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HPV OncoTect™ | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients with oropharyngeal cancer
- description
- Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test. Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results.
- interventionNames
- Diagnostic Test: HPV OncoTect™
Primary outcomes (1)
- measure
- Sensitivity is defined as the probability that the oncotectTM HPV test is positive if the cancer is HPV-induced.
- timeFrame
- up to 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Untreated oropharynx epidermoid carcinoma 2. Patient ≥ 18 years old 3. Patient affiliated to a social security scheme or beneficiary of such a scheme 4. Information to the patient or his legal representative and signature of informed consent Exclusion Criteria: 1. Non-oropharyngeal epidermoid carcinoma 2. Oropharyngeal epidermoid carcinoma previously treated
References
Publications (0)
Data not yet available
No reference posted for this study.